When are PCSK9 injections offered on the NHS? 

PCSK9 inhibitors are offered on the NHS to patients with high cholesterol who meet strict clinical criteria. These medications are typically reserved for individuals with familial hypercholesterolaemia or established cardiovascular disease whose LDL levels remain persistently high despite taking the maximum tolerated doses of statins and ezetimibe. 

What We’ll Discuss in This Article 

• The specific LDL cholesterol thresholds required for NHS eligibility. 

• Risk categories defined by NICE, including ‘high’ and ‘very high’ risk groups. 

• The requirement for ‘maximal therapy’ before moving to injectable treatments. 

• Biological causes that make some individuals resistant to standard oral tablets. 

• Medical triggers that prompt a specialist referral for advanced therapy. 

• Differences in how PCSK9 inhibitors function compared to traditional statins. 

• Using the BMI Calculator to support long-term cardiovascular health. 

Eligibility Criteria for PCSK9 Injections 

PCSK9 inhibitors are recommended as an option on the NHS when Low-Density Lipoprotein (LDL) concentrations remain persistently above specific thresholds despite maximal tolerated lipid-lowering therapy. This means patients must have tried the highest possible doses of standard medications like statins or shown a documented clinical intolerance to them before being considered. 

The NHS follows guidance from the National Institute for Health and Care Excellence (NICE) to determine who receives these injections. Eligibility is strictly tied to your blood test results and your medical history. ‘Persistently’ is defined as at least two consecutive LDL readings taken over a minimum period of three months while you are on your current treatment plan. 

Patient Category	Primary Prevention (No heart disease)	Secondary Prevention (Established heart disease)
Heterozygous FH	LDL > 5.0 mmol/L	LDL > 3.5 mmol/L
Non-Genetic (High Risk)	Not Recommended	LDL > 4.0 mmol/L
Non-Genetic (Very High Risk)	Not Recommended	LDL > 3.5 mmol/L

Clinical Conditions and Risk Categories 

PCSK9 injections are offered to those with primary hypercholesterolaemia, including the genetic form known as familial hypercholesterolaemia (FH), and those at high risk of further cardiovascular events. High risk includes a history of heart attack, stroke, or peripheral arterial disease, while very high risk refers to recurrent events or disease in multiple areas of the body. 

For individuals without a genetic diagnosis, these injections are strictly for ‘secondary prevention’. This means you must already have a diagnosis of cardiovascular disease to be eligible. The distinction between ‘high’ and ‘very high’ risk determines whether your LDL threshold is 4.0 mmol/L or 3.5 mmol/L. 

• High Risk: History of acute coronary syndrome, coronary revascularisation, or ischaemic stroke. 

• Very High Risk: Recurrent cardiovascular events or polyvascular disease (disease in more than one vascular bed). 

Underlying Causes of Resistance to Oral Therapy 

Some patients require PCSK9 inhibitors because their bodies are biologically resistant to the effects of oral statins or ezetimibe. This resistance is often caused by the overproduction of the PCSK9 protein, which prematurely destroys the receptors in the liver that are supposed to clear ‘bad’ cholesterol from the bloodstream. 

When these receptors are destroyed, the liver cannot effectively filter LDL from the blood, leading to high levels regardless of how little cholesterol you consume. In cases of Familial Hypercholesterolaemia (FH), a genetic mutation makes this process even more aggressive, often requiring advanced monoclonal antibody therapy to restore the liver’s natural filtering ability. 

Lifestyle and Medical Triggers for Switching to Injections 

The primary trigger for a specialist to offer PCSK9 injections is the failure of ‘maximally tolerated therapy’ to bring LDL levels below the NICE thresholds. Medical triggers also include ‘statin intolerance’, where a patient experiences severe and persistent side effects that prevent them from taking the dose required to protect their heart. 

If a patient’s LDL remains above 3.5 mmol/L or 4.0 mmol/L after three months of consistent statin and ezetimibe use, it triggers a clinical review. Lifestyle factors, such as maintaining a healthy weight, are encouraged alongside medication, but for those with genetic triggers or high baseline levels, advanced clinical intervention is the necessary step to reduce the risk of a secondary heart attack or stroke. 

Differentiation: PCSK9 Inhibitors vs. Standard Statins 

While statins work by slowing down the production of cholesterol inside the liver, PCSK9 inhibitors focus on the ‘clearance’ side of the equation. Statins block an enzyme called HMG-CoA reductase, whereas PCSK9 injections are monoclonal antibodies that prevent the destruction of LDL receptors, allowing the liver to ‘catch’ and remove more cholesterol from the blood. 

Feature	Standard Statins	PCSK9 Inhibitors
Form	Daily Tablet	Fortnightly/Monthly Injection
Primary Action	Blocks cholesterol production	Increases cholesterol clearance
Typical Reduction	30% to 50%	50% to 60%
Prescribed By	General Practitioner (GP)	Hospital Specialist (Lipid Clinic)

To Summarise 

PCSK9 injections are a powerful tool offered on the NHS for patients who cannot reach safe cholesterol targets using standard tablets alone. Eligibility is defined by LDL thresholds of 3.5 mmol/L to 5.0 mmol/L, depending on your risk of heart disease or genetic history. These treatments must be initiated by a specialist and are intended for long-term protection against serious cardiovascular events. 

If you experience severe, sudden, or worsening symptoms, such as crushing chest pain or sudden weakness on one side of your body, call 999 immediately. 

You may find our free BMI Calculator helpful for understanding or monitoring your symptoms, as weight management supports the overall effectiveness of your cardiovascular treatment plan. 

Authority Snapshot 

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being. This article covers the clinical eligibility and standards for PCSK9 inhibitors within the UK health system.